The Epstein-Barr Virus Glycoprotein gp150 Forms an Immune-Evasive Glycan Shield at the Surface of Infected Cells

PLoS Pathogens

Volumn 12, Issue 4, 2016, Pages

  Gram, Anna M ^a,b   Oosenbrug, Timo ^a   Lindenbergh, Marthe F S ^b   Büll, Christian ^c   Comvalius, Anouskha ^a   Dickson, Kathryn J I ^d   Wiegant, Joop ^a   Vrolijk, Hans ^a   Lebbink, Robert Jan ^b   Wolterbeek, Ron ^a   Adema, Gosse J ^c   Griffioen, Marieke ^a   Heemskerk, Mirjam H M ^a   Tscharke, David C ^d   Hutt Fletcher, Lindsey M ^e   Wiertz, Emmanuel J H J ^b   Hoeben, Rob C ^a   Ressing, Maaike E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Australian National University   (Australia)

^e LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; MICROSOMAL AMINOPEPTIDASE; PROTEINASE INHIBITOR; SIALIDASE; VIRUS GLYCOPROTEIN; BDLF-3 PROTEIN, HUMAN HERPESVIRUS 4; MEMBRANE PROTEIN; VIRAL PROTEIN;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMMUNE EVASION; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN DEGRADATION; SIALYLATION; VIRUS IMMUNITY; VIRUS REPLICATION; WESTERN BLOTTING; ANTIGEN PRESENTATION; EPSTEIN BARR VIRUS INFECTION; GENETIC TRANSDUCTION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; T LYMPHOCYTE;

ANTIGEN PRESENTATION; BLOTTING, WESTERN; EPSTEIN-BARR VIRUS INFECTIONS; FLOW CYTOMETRY; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNE EVASION; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICROSCOPY, CONFOCAL; T-LYMPHOCYTES; TRANSDUCTION, GENETIC; VIRAL PROTEINS;

EID: 84962752922     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005550     Document Type: Article

References (42)

1. Salio M, Silk JD, Jones EY, Cerundolo V, (2014) Biology of CD1- and MR1-restricted T cells. Annu Rev Immunol32: 323–366. doi: 10.1146/annurev-immunol-032713-12024324499274
2. Horst D, Geerdink RJ, Gram AM, Stoppelenburg AJ, Ressing ME, (2012) Hiding lipid presentation: viral interference with CD1d-restricted invariant natural killer T (iNKT) cell activation. Viruses4: 2379–2399. doi: 10.3390/v410237923202469
3. Pellett PE, Roizman B, editors (2007) The Family Herpesviridae: A Brief Introduction.
4. Horst D, Verweij MC, Davison AJ, Ressing ME, Wiertz EJ, (2011) Viral evasion of T cell immunity: ancient mechanisms offering new applications. Curr Opin Immunol23: 96–103. doi: 10.1016/j.coi.2010.11.00521146386
5. Epstein MA, Achong BG, Barr YM, (1964) Virus Particles in Cultured Lymphoblasts from Burkitt's Lymphoma. Lancet1: 702–703. 14107961
6. Taylor GS, Long HM, Brooks JM, Rickinson AB, Hislop AD, (2015) The immunology of Epstein-Barr virus-induced disease. Annu Rev Immunol33: 787–821. doi: 10.1146/annurev-immunol-032414-11232625706097
7. Pasquier B, Yin L, Fondaneche MC, Relouzat F, Bloch-Queyrat C, et al. (2005) Defective NKT cell development in mice and humans lacking the adapter SAP, the X-linked lymphoproliferative syndrome gene product. J Exp Med201: 695–701. 15738056
8. Rigaud S, Fondaneche MC, Lambert N, Pasquier B, Mateo V, et al. (2006) XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature444: 110–114. 17080092
9. Rooney CM, Smith CA, Ng CY, Loftin S, Li C, et al. (1995) Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet345: 9–13. 7799740
10. Ressing ME, van Gent M, Gram AM, Hooykaas M, Piersma S, et al., editors (2015) Immune evasion by Epstein-Barr virus.
11. Hislop AD, Ressing ME, van Leeuwen D, Pudney VA, Horst D, et al. (2007) A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med204: 1863–1873. 17620360
12. Zuo J, Quinn LL, Tamblyn J, Thomas WA, Feederle R, et al. (2011) The Epstein-Barr virus-encoded BILF1 protein modulates immune recognition of endogenously processed antigen by targeting major histocompatibility complex class I molecules trafficking on both the exocytic and endocytic pathways. J Virol85: 1604–1614. doi: 10.1128/JVI.01608-1021123379
13. van Gent M, Gram AM, Boer IG, Geerdink RJ, Lindenbergh MF, et al. (2015) Silencing the shutoff protein of Epstein-Barr virus in productively infected B cells points to (innate) targets for immune evasion. J Gen Virol96: 858–865. doi: 10.1099/jgv.0.00002125502648
14. Quinn LL, Zuo J, Abbott RJ, Shannon-Lowe C, Tierney RJ, et al. (2014) Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle. PLoS Pathog10: e1004322. doi: 10.1371/journal.ppat.100432225144360
15. Ressing ME, Keating SE, van Leeuwen D, Koppers-Lalic D, Pappworth IY, et al. (2005) Impaired transporter associated with antigen processing-dependent peptide transport during productive EBV infection. J Immunol174: 6829–6838. 15905524
16. Rao P, Pham HT, Kulkarni A, Yang Y, Liu X, et al. (2011) Herpes simplex virus 1 glycoprotein B and US3 collaborate to inhibit CD1d antigen presentation and NKT cell function. J Virol85: 8093–8104. doi: 10.1128/JVI.02689-1021653669
17. Zuo J, Currin A, Griffin BD, Shannon-Lowe C, Thomas WA, et al. (2009) The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog5: e1000255. doi: 10.1371/journal.ppat.100025519119421
18. Ressing ME, van Leeuwen D, Verreck FA, Gomez R, Heemskerk B, et al. (2003) Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition. Proc Natl Acad Sci U S A100: 11583–11588. 14504389
19. Borza CM, Hutt-Fletcher LM, (1998) Epstein-Barr virus recombinant lacking expression of glycoprotein gp150 infects B cells normally but is enhanced for infection of epithelial cells. J Virol72: 7577–7582. 9696856
20. Exley M, Garcia J, Wilson SB, Spada F, Gerdes D, et al. (2000) CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes. Immunology100: 37–47. 10809957
21. van de Weijer ML, Bassik MC, Luteijn RD, Voorburg CM, Lohuis MA, et al. (2014) A high-coverage shRNA screen identifies TMEM129 as an E3 ligase involved in ER-associated protein degradation. Nat Commun5: 3832. doi: 10.1038/ncomms483224807418
22. Griffin BD, Gram AM, Mulder A, Van Leeuwen D, Claas FH, et al. (2013) EBV BILF1 evolved to downregulate cell surface display of a wide range of HLA class I molecules through their cytoplasmic tail. J Immunol190: 1672–1684. doi: 10.4049/jimmunol.110246223315076
23. Paduraru C, Spiridon L, Yuan W, Bricard G, Valencia X, et al. (2006) An N-linked glycan modulates the interaction between the CD1d heavy chain and beta 2-microglobulin. J Biol Chem281: 40369–40378. 17071611
24. Gromme M, Uytdehaag FG, Janssen H, Calafat J, van Binnendijk RS, et al. (1999) Recycling MHC class I molecules and endosomal peptide loading. Proc Natl Acad Sci U S A96: 10326–10331. 10468607
25. Kurilla MG, Heineman T, Davenport LC, Kieff E, Hutt-Fletcher LM, (1995) A novel Epstein-Barr virus glycoprotein gp150 expressed from the BDLF3 open reading frame. Virology209: 108–121. 7747461
26. Nolan LA, Morgan AJ, (1995) The Epstein-Barr virus open reading frame BDLF3 codes for a 100–150 kDa glycoprotein. J Gen Virol76 (Pt 6): 1381–1392. 7782767
27. Eckhardt M, Gotza B, Gerardy-Schahn R, (1998) Mutants of the CMP-sialic acid transporter causing the Lec2 phenotype. J Biol Chem273: 20189–20195. 9685366
28. Rillahan CD, Antonopoulos A, Lefort CT, Sonon R, Azadi P, et al. (2012) Global metabolic inhibitors of sialyl- and fucosyltransferases remodel the glycome. Nat Chem Biol8: 661–668. doi: 10.1038/nchembio.99922683610
29. Francica JR, Varela-Rohena A, Medvec A, Plesa G, Riley JL, et al. (2010) Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoprotein. PLoS Pathog6: e1001098. doi: 10.1371/journal.ppat.100109820844579
30. Ritchie G, Harvey DJ, Stroeher U, Feldmann F, Feldmann H, et al. (2010) Identification of N-glycans from Ebola virus glycoproteins by matrix-assisted laser desorption/ionisation time-of-flight and negative ion electrospray tandem mass spectrometry. Rapid Commun Mass Spectrom24: 571–585. doi: 10.1002/rcm.441020131323
31. May JS, Coleman HM, Boname JM, Stevenson PG, (2005) Murine gammaherpesvirus-68 ORF28 encodes a non-essential virion glycoprotein. J Gen Virol86: 919–928. 15784886
32. Büll C, den Brok MH, Adema GJ, (2014) Sweet escape: sialic acids in tumor immune evasion. Biochim Biophys Acta1846: 238–246. doi: 10.1016/j.bbcan.2014.07.00525026312
33. Cohen M, Elkabets M, Perlmutter M, Porgador A, Voronov E, et al. (2010) Sialylation of 3-methylcholanthrene-induced fibrosarcoma determines antitumor immune responses during immunoediting. J Immunol185: 5869–5878. doi: 10.4049/jimmunol.100163520956342
34. Schneider F, Kemmner W, Haensch W, Franke G, Gretschel S, et al. (2001) Overexpression of sialyltransferase CMP-sialic acid:Galbeta1,3GalNAc-R alpha6-Sialyltransferase is related to poor patient survival in human colorectal carcinomas. Cancer Res61: 4605–4611. 11389097
35. Büll C, Boltje TJ, van Dinther EA, Peters T, de Graaf AM, et al. (2015) Targeted delivery of a sialic acid-blocking glycomimetic to cancer cells inhibits metastatic spread. ACS Nano9: 733–745. doi: 10.1021/nn506196425575241
36. Huppa JB, Davis MM, (2013) The interdisciplinary science of T-cell recognition. Adv Immunol119: 1–50. doi: 10.1016/B978-0-12-407707-2.00001-123886063
37. Cook JD, Lee JE, (2013) The secret life of viral entry glycoproteins: moonlighting in immune evasion. PLoS Pathog9: e1003258. doi: 10.1371/journal.ppat.100325823696729
38. Kropff B, Burkhardt C, Schott J, Nentwich J, Fisch T, et al. (2012) Glycoprotein N of human cytomegalovirus protects the virus from neutralizing antibodies. PLoS Pathog8: e1002999. doi: 10.1371/journal.ppat.100299923133379
39. Machiels B, Lete C, Guillaume A, Mast J, Stevenson PG, et al. (2011) Antibody evasion by a gammaherpesvirus O-glycan shield. PLoS Pathog7: e1002387. doi: 10.1371/journal.ppat.100238722114560
40. van den Wollenberg DJ, Dautzenberg IJ, van den Hengel SK, Cramer SJ, de Groot RJ, et al. (2012) Isolation of reovirus T3D mutants capable of infecting human tumor cells independent of junction adhesion molecule-A. PLoS One7: e48064. doi: 10.1371/journal.pone.004806423110175
41. Adhikary D, Behrends U, Boerschmann H, Pfunder A, Burdach S, et al. (2007) Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy. PLoS One2: e583. 17611619
42. Büll C, Boltje TJ, Wassink M, de Graaf AM, van Delft FL, et al. (2013) Targeting aberrant sialylation in cancer cells using a fluorinated sialic acid analog impairs adhesion, migration, and in vivo tumor growth. Mol Cancer Ther12: 1935–1946. doi: 10.1158/1535-7163.MCT-13-027923974695